ArticleCancer medicine2025
circTUBD1-hnRNPK Regulates the Proliferation and Migration of LSCC by Targeting CCAR1.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLaryngeal squamous cell carcinoma (LSCC) is one of the most prevalent malignancies of the head and neck region. Circular RNAs (circRNAs) have been found to exhibit abnormal expression patterns in various tumors and play pivotal roles in tumorigenesis and tumor progression.
methodsFunctional assays assessed proliferation, migration, and invasion. Mechanistic studies were performed to explore the interaction between circTUBD1 and heterogeneous nuclear ribonucleoprotein K (hnRNPK), as well as its regulation of Cell Cycle and Apoptosis Regulator 1 (CCAR1). In vivo experiments confirmed circTUBD1's role in tumor growth and metastasis.
resultsWe discovered that circTUBD1 is significantly upregulated in LSCC and promotes the proliferation, invasion, and migration of LSCC cells. circTUBD1 forms a circRNA-protein complex with hnRNPK and facilitates LSCC progression by regulating CCAR1. Furthermore, in vivo experiments in mice demonstrated that silencing circTUBD1 inhibits the proliferation and metastasis of LSCC.
conclusionsThis study provides evidence that circTUBD1 is a potential tumor marker for LSCC and underscores the therapeutic potential of targeting circTUBD1 in this cancer type.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.